REFRACTORY MARGINAL ZONE LYMPHOMA
Clinical trials for REFRACTORY MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough blood cancers: early trial of Bcl-2 blocker begins
Disease control OngoingThis study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 05:55 UTC
-
New combo tackles tough lymphoma: early trial shows promise
Disease control OngoingThis early-phase study tests a combination of two drugs, ibrutinib and lenalidomide, in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The main goals are to find the safest dose and understand side effects. About 39 participan…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New Triple-Drug attack shows promise against tough lymphomas
Disease control OngoingThis study tests a new drug combination (ALX148, rituximab, and lenalidomide) in people with slow-growing or fast-growing B-cell non-Hodgkin lymphoma that has not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink or eliminate tumors. …
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival s…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC